JNJ

233.93

+2.23%↑

ISRG

486.38

-2.61%↓

ABT

108.27

-1.61%↓

RDY

13.85

+5.16%↑

NEOG

10.63

+2.41%↑

JNJ

233.93

+2.23%↑

ISRG

486.38

-2.61%↓

ABT

108.27

-1.61%↓

RDY

13.85

+5.16%↑

NEOG

10.63

+2.41%↑

JNJ

233.93

+2.23%↑

ISRG

486.38

-2.61%↓

ABT

108.27

-1.61%↓

RDY

13.85

+5.16%↑

NEOG

10.63

+2.41%↑

JNJ

233.93

+2.23%↑

ISRG

486.38

-2.61%↓

ABT

108.27

-1.61%↓

RDY

13.85

+5.16%↑

NEOG

10.63

+2.41%↑

JNJ

233.93

+2.23%↑

ISRG

486.38

-2.61%↓

ABT

108.27

-1.61%↓

RDY

13.85

+5.16%↑

NEOG

10.63

+2.41%↑

Search

Stevanato Group SpA

Abrir

SetorSaúde

15.38 1.92

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15

Máximo

15.78

Indicadores-chave

By Trading Economics

Rendimento

10M

49M

Vendas

23M

303M

P/E

Médio do Setor

28.8

90.422

EPS

0.162

Rendimento de Dividendos

0.31

Margem de lucro

16.205

Funcionários

5,521

EBITDA

10M

73M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+73.3% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.31%

2.13%

Próximos Ganhos

5 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2B

4.7B

Abertura anterior

13.46

Fecho anterior

15.38

Sentimento de Notícias

By Acuity

50%

50%

147 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Stevanato Group SpA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 de fev. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 de fev. de 2026, 23:28 UTC

Conversa de Mercado

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 de fev. de 2026, 23:23 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 de fev. de 2026, 22:57 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 22:08 UTC

Conversa de Mercado

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 de fev. de 2026, 21:51 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de fev. de 2026, 21:49 UTC

Ganhos

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 de fev. de 2026, 21:39 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:36 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 de fev. de 2026, 21:34 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:28 UTC

Aquisições, Fusões, Aquisições de Empresas

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 21:23 UTC

Ganhos

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 de fev. de 2026, 21:19 UTC

Ganhos

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:10 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:08 UTC

Ganhos

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 de fev. de 2026, 21:07 UTC

Ganhos

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Net $608.7M >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Rev $1.41B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q EPS 24c >PLTR

2 de fev. de 2026, 20:40 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparação entre Pares

Variação de preço

Stevanato Group SpA Previsão

Preço-alvo

By TipRanks

73.3% parte superior

Previsão para 12 meses

Média 27 USD  73.3%

Máximo 30 USD

Mínimo 24 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Stevanato Group SpA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

21.56 / 22.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

147 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat